Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUM: Thalidomide vs Dexamethasone in Relapsed Refractory Multiple Myeloma
NCT00452569Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of thalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Feb 2006; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00452569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452569.